LEADER 03370nam  2200637Ia 450 
001 9910818045803321
005 20200520144314.0
010   $a0-19-934900-2
010   $a1-282-76325-3
010   $a9786612763250
010   $a0-19-970788-X
035   $a(CKB)2560000000016328
035   $a(EBL)584585
035   $a(OCoLC)667231115
035   $a(SSID)ssj0000424194
035   $a(PQKBManifestationID)12164644
035   $a(PQKBTitleCode)TC0000424194
035   $a(PQKBWorkID)10471138
035   $a(PQKB)11731995
035   $a(StDuBDS)EDZ0000173009
035   $a(MiAaPQ)EBC584585
035   $a(Au-PeEL)EBL584585
035   $a(CaPaEBR)ebr10416906
035   $a(CaONFJC)MIL276325
035   $a(PPN)161875564
035   $a(EXLCZ)992560000000016328
100   $a20100216d2010      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aNon-dopamine lesions in Parkinson's disease$b[electronic resource] /$fedited by Glenda M. Halliday, Roger A. Barker, Dominic B. Rowe
210   $aNew York $cOxford University Press$d2010
215   $a1 online resource (337 p.)
300   $aDescription based upon print version of record.
311   $a0-19-537108-9 
320   $aIncludes bibliographical references and index.
327   $aContents; Contributors; Chapter 1: Lesions Associated with the Classic Triad of Parkinsonian Motor Features; Chapter 2: Lesions Associated with Motor Speech; Chapter 3: Lesions Associated with Eye Movements; Chapter 4: Olfactory Dysfunction in Parkinson's Disease and Related Disorders; Chapter 5: Lesions Associated with Autonomic Dysfunction A: Swallowing Disorders and Drooling; Chapter 6: Lesions Associated with Pain and Sensory Abnormalities; Chapter 7: Lesions Associated with Sleep Disturbances; Chapter 8: Lesions Associated with Depression and Apathy
327   $aChapter 9: Lesions Associated with Dyskinesias and the Dopamine Dysregulation SyndromeChapter 10: Lesions Associated with Visual Hallucinations and Psychoses; Chapter 11: Lesions Associated with Cognitive Impairment and Dementia; Chapter 12: Systemic Manifestations of Parkinson's Disease; Index
330   $aParkinson's disease becomes apparent only after substantial loss (>60%) of the dopamine neurons in the substantia nigra. By this time there has already been widespread neural inclusion formation in the peripheral and central nervous system of patients with the disease, although this has only been recognized more recently. Degeneration in these widespread regions of the peripheral and central nervous system is now known to impact on disease symptoms, progression and treatment over time. This book aims to provide a comprehensive review of these non-dopamine lesions in Parkinson's disease by asse
606   $aParkinson's disease$xPathophysiology
606   $aBrain$xDiseases
615  0$aParkinson's disease$xPathophysiology.
615  0$aBrain$xDiseases.
676   $a616.8/33
701   $aHalliday$b Glenda M$01612122
701   $aBarker$b Roger A.$f1961-$01612123
701   $aRowe$b Dominic B$01612124
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910818045803321
996   $aNon-dopamine lesions in Parkinson's disease$93940737
997   $aUNINA